Collaboration brings together OnDosis' Dosage Manager precision-dosing platform and Adare's integrated CDMO and controlled-substance manufacturing expertise to establish U.S. commercial-scale manufacturing for Imfocy®, OnDosis' lead ADHD program.

Aktieägarna i OnDosis AB, kallas härmed till extra bolagsstämma måndagen den 15 juni 2026 kl. 17.00 i Bolagets lokaler i GoCo House, 5 tr, Gemenskapens gata 9 i Mölndal. Insläpp och registrering sker vid entrén kl. 16.30. Styrelsen har beslutat att även låta aktieägare delta i extra bolagsstämman digitalt. // The shareholders of OnDosis AB, are hereby given notice of an extraordinary general meeting to be held on Monday 15 June 2026 at 17.00 at the Company's premises at GoCo House, 5th floor, Gemenskapens gata 9 in Mölndal. Admission and registration will take place at the entrance at 16.30. The board of directors has resolved to also allow shareholders to participate in the extraordinary general meeting digitally.

Aktieägarna i OnDosis AB, kallas härmed till årsstämma tisdagen den 21 april 2026 kl. 10.00 i Bolagets lokaler i GoCo House, 5 tr, Gemenskapens gata 9 i Mölndal. // The shareholders of OnDosis AB, are hereby given notice to attend the Annual General Meeting to be held on Tuesday 21 April 2026 at 10.00 a.m. at the Company’s premises at GoCo House, 5th floor, Gemenskapens gata 9 in Mölndal.

Partnership brings together Revio’s drug product innovation capabilities, its AI-platform rethink Tx and OnDosis’ proprietary Dosage Manager device & associated technology platform to create IP-rich differentiated specialty products.

Diamond Therapeutics Inc. (“Diamond”), a clinical-stage drug development company and OnDosis, a developer of precision dosing technologies for oral solid medicines, announced today that they have entered into an agreement regarding the use of the OnDosis drug delivery platform, the Dosage Manager, in Diamond’s psychoactive low-dose psilocybin programs.

Styrelsens förslag till beslut om bemyndigande för styrelsen att emittera aktier eller aktier och teckningsoptioner för att fullgöra skyldigheter under konvertibla låneavtal.

OnDosis årsredovisning 2024 / OnDosis Annual General report 2024.

The shareholders of OnDosis AB, are hereby invited to attend the Annual General Meeting to be held on Monday 5 May 2025 at 10:00 a.m. at the OnDosis's premises at GoCo House, 5th floor, Gemenskapens gata 9 in Mölndal, Sweden. Admission and registration take place at the entrance at 09:30. The board of directors has decided to also allow shareholders to participate in the annual general meeting digitally.

Aktieägarna i OnDosis AB kallas härmed till årsstämma måndagen den 5 maj 2025 kl. 10.00 i OnDosis lokaler i GoCo House, 5 tr, Gemenskapens gata 9 i Mölndal. Insläpp och registrering sker vid entrén kl. 09.30. Styrelsen har beslutat att även låta aktieägare delta i årsstämman digitalt.

Liège, Belgium and Gothenburg, Sweden – October 15, 2024: AARDEX Group, a leader in managing drug exposure in clinical trials, and precision medicine innovators, and OnDosis, a game changer in precision dosing of oral solid medicines through the novel Dosage Manager device, have announced a partnership aimed at revolutionizing precision dosing and optimizing exposure-response in clinical trials. This collaboration is set to bring next-level innovation to drug development, ensuring more effective and safer treatments for patients.